Amivantamab Plus Lazertinib Added to NCCN for Frontline NSCLC

Panelists discuss the National Comprehensive Cancer Network (NCCN) guidelines for first-line treatment of EGFR-mutant metastatic non–small cell lung cancer (NSCLC), emphasizing the recommended therapies and best practices for patient management.

EP: 1.Overview of MARIPOSA Study

EP: 2.Amivantamab Plus Lazertinib Clinical Efficacy

EP: 3.Safety Considerations for Frontline Amivantamab Plus Lazertinib

Now Viewing

EP: 4.Amivantamab Plus Lazertinib Added to NCCN for Frontline NSCLC

EP: 5.Putting Amivantamab Plus Lazertinib Into Practice

EP: 6.Longer Follow-Up Data Maintain Lasting Responses With Amivantamab/ Lazertinib in EGFR-Mutant NSCLC

Recent Videos

Related Content

---

Longer Follow-Up Data Maintain Lasting Responses With Amivantamab/ Lazertinib in EGFR-Mutant NSCLC

ONCOLOGY Staff

December 28th 2024

Article

Joshua K. Sabari, MD, and Sandip P. Patel, MD, discussed long-term findings from the phase 3 MARIPOSA trial.

Related Content

---

Longer Follow-Up Data Maintain Lasting Responses With Amivantamab/ Lazertinib in EGFR-Mutant NSCLC

ONCOLOGY Staff

December 28th 2024

Article

Joshua K. Sabari, MD, and Sandip P. Patel, MD, discussed long-term findings from the phase 3 MARIPOSA trial.